Alopecia Areata - Epidemiology Forecast - 2036

Alopecia Areata Insights and Trends

• Alopecia areata is a prevalent autoimmune skin condition that results in hair loss, typically on the scalp, face, and occasionally other parts of the body. This condition can affect individuals across all age groups, genders, and ethnicities. Characterized by the body's immune system mistakenly attacking hair follicles, alopecia areata often leads to patchy hair loss, though its severity can vary widely among individuals.
• According to DelveInsight's analysis, alopecia areata reported approximately 2 million diagnosed prevalent cases in the 7MM (the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan) in 2025.
• In 2025, the majority of cases were observed in the before 40 age group, accounting for approximately 530,000 cases, while more than 100,000 cases were reported in the after-40 age group in the US. The prevalence of alopecia areata is expected to rise more in the before-40 age group due to the earlier onset of autoimmune conditions and heightened stress levels. These factors contribute to a higher likelihood of developing the condition at a younger age.
• Alopecia areata's differential diagnosis includes conditions causing non-scarring hair loss, like tinea capitis, trichotillomania, and telogen effluvium. Associated comorbidities include autoimmune diseases, atopic conditions, psychiatric disorders, and deficiencies. Comorbidities vary with age and severity, with children often showing atopy and older adults more prone to thyroid diseases. Symptoms and specific clinical indications guide screening.

DelveInsight's "Alopecia Areata -Epidemiology, Forecast - 2036" report delivers an in depth understanding of alopecia areata, historical and forecasted epidemiology in the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.

Alopecia Areata Understanding and Diagnosis Algorithm

Alopecia Areata Overview and Diagnosis

Alopecia areata is a common autoimmune skin disease, causing hair loss on the scalp, face, and sometimes on other areas of the body, affecting people of all ages, both sexes and all ethnic groups can develop alopecia areata. It is one of many recognized forms of alopecia; alopecia areata is the second most common form after androgenetic alopecia. It often first appears during childhood and can be different for everyone who has it. Visible symptoms include small, coin-sized, round patches of baldness on the scalp, although hair elsewhere, such as the beard, eyebrows, eyelashes, body, and limbs, can be affected. In some people, larger areas are affected, and occasionally, it can involve the whole scalp (alopecia totalis) or even the entire body and scalp.

The evaluation of an alopecia areata patient should include a comprehensive medical and family history and a thorough examination of the scalp, the face, and the entire body, including the nails. This should always be complemented by dermatoscopy and a hair pull test. When clinical findings do not allow a definite diagnosis, additional investigations may be necessary, such as a scalp biopsy, a fungal culture, or serology for other autoimmune diseases or infectious diseases.

Hair and scalp dermatoscopy, also known as trichoscopy, is an easy, noninvasive diagnostic technique helpful in diagnosing and following scalp diseases. Dermatoscopy is especially crucial for differentiating nonscarring and scarring hair diseases, confirming the diagnosis of alopecia areata, and evaluating the disease activity. The most common dermatoscopic findings in alopecia areata are yellow dots, black dots, broken hair, exclamation mark hair, and vellus hair, while other less frequently described findings are upright hair, tapered hair, pigtail hair, and Pohl-Pinkus constrictions.

Alopecia Areata Epidemiology

Key Findings from Alopecia Areata Epidemiological Analysis and Forecast

• In 2025, the US accounted for the highest prevalent cases of alopecia areata with more than 780,000 prevalent cases, and around 630,000 diagnosed prevalent cases which are expected to increase by 2036.
• In 2025, the UK reported the highest number of diagnosed prevalent cases of alopecia areata among the EU4 and the UK, with more than 300,000 cases. Spain followed with more than 170,000 cases, while Italy recorded the lowest diagnosed prevalence, with nearly 100,000 cases.
• In 2025, Japan reported approximately 170,000 diagnosed prevalent cases of alopecia areata in females and more than 100,000 cases in males, with numbers projected to rise by 2036.
• In 2025, females accounted for around 63% of alopecia areata cases in the EU4 and the UK, while males represented 37%. These gender-specific patterns are expected to grow, with overall prevalence projected to increase by 2036.
• In 2025, around 14% of alopecia areata cases in the EU4 and the UK were mild, 45% moderate, and 41% severe. These severity patterns are expected to continue, with overall prevalence anticipated to increase by 2036.

Scope of the Report:

• The report covers a segment of key events, an executive summary, a descriptive overview of alopecia areata, explaining its causes, signs and symptoms, and pathogenesis.
• Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of the diagnosis rate, and disease progression.

Report Insights

Alopecia areata Patient Population Forecast

Report Key Strengths

• Epidemiology-based (Epi-based) Bottom-up Forecasting
• Artificial Intelligence (AI)-Enabled Market Research Report
• 11-Year Forecast

FAQs:

• What are the disease risks, burdens, and unmet needs of alopecia areata?
• What will be the growth opportunities across the 7MM concerning the patient population with alopecia areata?
• What is the alopecia areata prevalence in the US, EU4 (Germany, France, Italy, and Spain), the UK, and Japan?
• What is the historical and forecasted alopecia areata patient pool in the US, EU4 (Germany, France, Italy, and Spain), the UK, and Japan?

Reasons to Buy:

• Insights on alopecia areata burden and disease prevalence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
• To understand key opinion leaders' perspectives around the diagnostic challenges to overcome barriers in the future.
• Detailed insights on various factors hampering disease diagnosis and other existing diagnostic challenges.
• Clear methodology, validated assumptions, and data-driven rationale to assess the alopecia areata epidemiology analysis and patient population trends.